We have been committed to giving full play to the advantages of targeted agents and biotechnology, researching and developing innovative products such as new high-end pharmaceutical agents and gene recombinant biotechnology drugs. At present, the company has built three technology platforms: based on the receptor active targeting agent technology platform, a series of active targeting new agents can be developed; Based on yeast expression system platform, macromolecular therapeutic drugs can be developed. Protein drug long-acting technology platform, which can design a series of long-acting protein drugs through pegylated drugs. The company continues to enrich the RESEARCH and development pipeline, the treatment field mainly covers tumor, endocrine, blood, nervous system diseases. In addition, we continue to maintain industry exchanges with the world's top pharmaceutical RESEARCH and development institutions, continue to follow the forefront of innovative drugs, and continue to seek cooperation and opportunities in the forefront of innovative drug research and development.